MissionIR's  Instablog

Oncothyreon recently announced that the company had enrolled the first patient for the Phase 1 trial of their ONT-10 vaccine product, intended for cancer patients. The trial is intended to evaluate the safety and immunogenicity of ONT-10 in patients.

Oncothyreon is focused on developing therapeutic products for cancer treatment, with the goal of bringing to market synthetic vaccines and targeted small molecules that could give cancer patients a higher quality of life and better outcome after diagnosis. ONT-10 targets MUC1, a tumor-associated antigen present on many types of human malignant tumors, including lung, breast, colorectal, prostate, and ovarian cancer. ONT-10 is intended to stimulate the immune response in patients. Preclinical testing in mice has shown effective against MUC1.

The Phase 1 trial will consist of two parts: to discover the maximum recommended dose of ONT-10 either once every other week or once every week over an eight week period via an escalating schedule of administration of the drug. The second part will investigate the safety of administering the drug at its maximum dosage over a further period.

Robert L. Kirkman, M.D., president and CEO of Oncothyreon, said, "We are excited to begin this trial of our proprietary therapeutic vaccine candidate ONT-10. We hope that this trial will demonstrate in cancer patients that ONT-10 can stimulate both antibodies and immune cells directed at MUC1, as it has in animal models. We are also looking forward to obtaining the first human data with the adjuvant component of ONT-10, a fully synthetic lipid A analog called PET-Lipid A, which was developed at Oncothyreon."

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html